Breaking News

Researchers re-analyzed throat swabs collected from patients in Wuhan with influenza-like-illness and found that some were positive for SARS-Cov-2.

The company said that three of its clinical laboratories have passed a COVID-19 external quality assessment by China's National Center for Clinical Laboratories.

The company said its product and services revenues were about $24.5 million for the quarter, 15 percent higher than the same period last year.

The assay is a real-time RT-PCR test designed for the qualitative detection of specific sequences of the SARS-CoV-2 N gene in respiratory specimens.

The company said that its preliminary revenues are expected to be down almost 8 percent year over year due to the pandemic.

Luminex said that its Q1 molecular diagnostics revenues are anticipated to rise more than 25 percent year over year, driven by SARS-CoV-2 test sales.

The NIGMS repository holds and distributes over 11,700 unique cell lines, as well as more than 6,300 DNA samples, representing over 1,000 heritable diseases.

Second Genome will use its Microbiome Analytics platform to identify novel biomarkers linked to clinical responses to Gilead's investigational medicines.

The company said that as the COVID-19 pandemic spread throughout the world, it saw a "significant reduction in customer activity" by late March.

The test is a real-time RT-PCR kit designed to detect SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs, as well as bronchoalveolar lavage.

The diagnostic will be covered when patients are tested according to the Japanese Organization of Hereditary Breast and Ovarian Cancer's criteria.

The approach deconvolutes admixed individuals' ancestries and develops polygenic risk scores based on each component that can then be combined.